Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2024 | Pooled fecal allogeneic microbiotherapy to treat refractory gastrointestinal acute GvHD

Florent Malard • 11 Apr 2024
EBMT 2024
General MaaT013 Ruxolitinib

Florent Malard, MD, PhD, Saint-Antoine Hospital and Sorbonne University, Paris, France, discusses the findings of a study in which 140 patients with refractory gastrointestinal acute graft-versus-host disease (GI-aGvHD) were treated with pooled fecal allogeneic microbiotherapy as part of an early access program in Europe. The majority of patients were resistant to steroids and additional lines of treatment, namely ruxolitinib. Patients received three doses of MaaT013 as an enema, and the efficacy and safety of the therapy were assessed. This interview took place at the 50th Annual Meeting of the EBMT in Glasgow, Scotland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Florent Malard

2:44
Comparing CAR-T products for aggressive B-cell lymphoma: axi-cel versus tisa-cel
Florent Malard • 11 Apr 2024
1:44
PHOEBUS trial: oral fecal microbiotherapy for increasing OS in patients undergoing alloSCT
Florent Malard • 11 Apr 2024
2:24
Manipulating the gut microbiome to improve outcomes of alloSCT for hematological malignancies
Florent Malard • 11 Apr 2024
2:04
Retrospective study on the outcomes of patients with myeloma treated with cilta-cel and ide-cel
Florent Malard • 20 May 2023

Related Videos

2:20
EBMT diagnostic criteria for TMA post-alloSCT and the role of complement activation
Jacopo Mariotti • 15 Apr 2024
5:42
Promising therapeutic efficacy of EBV-specific T-cell immunotherapy tabelecleucel in PTLD
Nina Worel • 25 Apr 2024
4:52
The collaboration of the EBMT and ISCT for the development and monitoring of ATMPs and SoHo
Nina Worel • 25 Apr 2024
4:24
Investigating production failure and out-of-specification production of CAR T-cell therapeutics
Nina Worel • 25 Apr 2024
The content of VJHemOnc is intended for healthcare professionals